bioAffinity Technologies, Inc. (BIAF) · Nov 19, 2026 · Other events
Adoption growth — Test unit sales +109%; ordering physicians +89%; existing-physician orders +48%
bioAffinity’s CyPath update highlights faster physician adoption and repeat orders, but the federal channel remains an opportunity—not reported revenue.
bioAffinity is a very small commercial-stage diagnostics company trying to turn CyPath Lung from a niche laboratory-developed test into a repeat-use lung-cancer screening product; the latest quarterly disclosure showed roughly $1.1 million of nine-month testing revenue, while cash was expected to fund operations only through March 2027.
The core commercial signal is genuinely encouraging: the filing reports test unit sales up 109%, ordering physicians up 89%, and orders from existing physicians up 48%, pointing to both new account adoption and deeper repeat use. 〔0〕 Those figures are better than the headline 100% year-to-date unit-growth figure in the company’s recent Q3 results release, although the metrics are not a substitute for reported revenue or cash generation.
Most of the strategic news is already known: the AvMEDICAL federal distribution agreement was announced in August and gives bioAffinity access to VA and other government procurement channels, but the filing explicitly says that access does not equal completed sales. 〔1〕 The update therefore strengthens the commercialization narrative without yet proving that the federal channel is converting into material revenue.
The pipeline discussion remains optional upside rather than a current business change: asthma/COPD diagnostics and the siRNA skin-cancer work are still research programs separate from CyPath Lung’s commercialization. 〔2〕
Bottom line: This is a modestly better adoption update, not a rewritten company story. Physician usage appears to be accelerating, but the filing adds little hard evidence on revenue conversion, cash durability, or federal sales beyond what investors had already learned.
FY 2026 results and Q4 CyPath Lung sales update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!